According to a May 29 post on Chinese social media platform WeChat, a vaccine is expected to be ready in the market by the end of this year or early 2021. Phase II clinical trials of vaccines developed by the Wuhan Institute of Biological Products and the Beijing Institute of Biological Products have begun.
Both groups are affiliated with the state-owned pharmaceutical group Sinofarm. Its management is overseen by the Asset Supervision and Administration Commission. According to the article, the Beijing Institute of Biological Products has an annual production capacity of 10 million to 12 million doses. But none of the companies have responded.
Content Highlights: 2,000 People In Trials, Coronavirus Vaccine Likely By Year-End: China